posted on 2025-05-01, 01:43authored byXinxin Huang, Huixian Zhou, Ting Tan, Yun Luo
Methylglyoxal (MGO)
has driven interest as a major precursor of
advanced glycation end products due to it being closely implicated
in the pathogenesis of diabetic kidney disease (DKD). Therefore, it
is critical for seeking active scavenger-targeted MGO to mitigate
the development of DKD. Previous studies demonstrated that naringenin
(Nar) has a remarkable therapeutic effect on DKD. However, whether
Nar could scavenge MGO in diabetic mice remains virtually unknown.
This work aims to investigate the effect and mechanism of scavenging
MGO by Nar in diabetic mice. Liquid chromatography coupled to tandem
mass spectrometry (LC–MS/MS) was applied for investigating
the scavenging capacity and mechanism of Nar on MGO in diabetic mice.
The results indicated that Nar could significantly scavenge MGO in
diabetic mice based on the formation of mono-MGO-Nar. In addition,
two mono-MGO-Nar nanoparticles were purified, and their structures
were deduced as 3-MGO-Nar using LC–MS/MS and NMR spectroscopic
analyses. Furthermore, the dose-dependent scavenge effect of Nar on
MGO in diabetic mice was elucidated by quantifying mono-MGO-Nar in
urine and feces using LC–MS/MS. In summary, our results first
demonstrated that targeting the MGO burden may be the new mechanism
of Nar combating DKD.